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Summary
Objective: To examine the relation between serum insulin-like growth factor I (IGF-I) levels and both
incident and progressive radiographic knee osteoarthritis (OA) in the Framingham Osteoarthritis Study.
Design: Subjects had bilateral weight-bearing, anterior–posterior knee radiographs performed in
1983–1985 and again in 1992–1993. IGF-I levels were measured from blood specimens obtained in
1988–1989 by a competitive binding radio-immunoassay (RIA) after separation with octadecasilyl-silica
cartridges of serum IGF-I from binding proteins. Participants without baseline radiographic OA
[Kellgren and Lawrence grades (K&L) = 0–1] were classified as having incident disease if they had
K&L r 2 grades at follow-up. Progressive OA was defined as an increase in K&L score of r 1 in knees
with baseline OA (K&L r 2). All analyses were knee-based and sex-specific. We examined IGF-I tertiles
in relation to the risk of incident and progressive radiographic OA separately, adjusting for age, body
mass index (BMI), and baseline K&L score, and used generalized estimating equations to adjust for the
correlation between fellow knees.
Results: Four hundred and forty-one participants had knee radiographs and serum IGF-I levels
measured. No associations were found for serum IGF-I levels and incident [women: OR = 0.9 (0.6–1.7),
men OR = 1.2 (0.6–2.6)] or progressive [women OR = 0.9 (0.6–1.6), men OR = 0.9 (0.3–3.0)] radiographic knee
OA in either sex. Neither did we observe any association between IGF-I and worsening of individual
radiographic features of OA (i.e., osteophyte growth and joint space loss).
Conclusion: In summary, this longitudinal study did not demonstrate any association of serum IGF-I
and incident or progressive radiographic knee OA. Further studies are needed to clarify the role of
IGF-I in OA.
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Introduction
Cartilage matrix integrity is normally maintained
by a balance between the effects of catabolic
cytokines and growth factors. A disruption in this
equilibrium resulting in increased cartilage break-
down is thought to contribute to the pathogenesis
of osteoarthritis (OA) [1]. Insulin-like growth
factor (IGF-I) has been shown to promote type II
collagen and proteoglycan synthesis [2–5], to
inhibit matrix degradation in vitro [6], and to be
anabolic for articular cartilage in vivo [7].
Previous studies of serum IGF-I levels and OA
have demonstrated conflicting results. Cross-sec-
tional studies have reported high [8], low [9], and
normal levels of IGF-I [10, 11] in subjects with OA
compared to controls. The only longitudinal study
published to date found a positive correlation
between IGF-I levels and OA progression in
subjects with pre-existing OA [12]. The develop-
ment of new disease (incident OA) has not been
addressed in prior studies.
Recent studies suggest that risk factors
for incident and progressive OA might differ.
Knee OA progression, and not incidence, has
been linked to both low bone mineral density [13]
and low serum levels of vitamin D [14], whereas
knee pain, injury, and physical activity were
found to influence incident but not progressive
OA [15].
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Based on the anabolic actions of IGF-I on
chondrocytes, we hypothesized that decreased
serum IGF-I is associated with an increased risk of
knee OA. To test this hypothesis, we examined the
relation of serum IGF-I and (1) incident and (2)
progressive radiographic knee OA in a large
population based cohort.
Methods
participants
The study participants were members of the
Framingham Osteoarthritis Study, which has been
extensively described in previous publications [16,
17]. In brief, the Framingham Osteoarthritis Study
includes members of the Framingham Heart Study,
a population based cohort followed since 1948, who
were evaluated for radiographic knee OA at
biennial examinations 18 (1983–1985) and 22
(1992–1993).
We performed a nested case–control study in
which all participants with incident and
progressive OA (defined below) were included as
cases. For the incident case group we randomly
drew up to three controls from all subjects without
knee OA at baseline. For the OA progression
analysis all those with baseline OA were included
as controls. As part of their routine exam, blood
was taken from the participants at biennial exam
20 (1988–1989) which was centrifuged and stored at
- 70° F. All people participating in this study were
healthy enough to attend the Framingham clinical
exams from 1983 through 1993.
radiographs
Each participant had bilateral weight-bearing,
anterior–posterior knee radiographs. Knee
radiographs were scored using a modified
Kellgren–Lawrence Scale (K&L) based on the
presence of joint space narrowing and/or
osteophytes, where 0 = no osteophyte or joint space
narrowing, 1 = questionable osteophyte(s) and/or
joint space narrowing, 2 = definite small
osteophyte(s) and/or mild joint space narrowing,
3 = definite moderate osteophyte(s) and or
moderate joint space narrowing of at least 50%,
and 4 = definite large osteophyte(s) and severe joint
space narrowing. Total knee replacements were
scored as 4. In addition, the presence and severity
of osteophytes and joint space narrowing were
scored separately for each joint (0 = normal,
1 = mild, 2 = moderate, 3 = severe) based on an atlas
of standard radiographic features. We did not
measure joint space narrowing using a ruler based
on the findings of Spector et al. [18] which found
that this method did not offer any advantage over
qualitative measures using a 0–3 scale.
All radiographs were scored by one of two
radiologists specializing in musculoskeletal
radiology. Intraobserver agreement for
radiographic knee OA based on K&L r 2, the
presence of osteophytes, and the presence of joint
space narrowing was kappa (k) = 0.91, 0.72, and 0.79
(all P Q 0.001), respectively. The interobserver
reliability for these measures was moderate
(k = 0.50, P Q 0.025, k = 0.50, P Q 0.001, and k = 0.65,
P Q 0.001). Because of the modest interobserver
reliability obtained, knee radiographs were
subsequently reread by a second set of readers,
using a strategy described elsewhere in detail [17].
A consensus reading was used in the analyses
reported here.
classification of oa
Incident OA was defined as subjects without
baseline radiographic OA (K&L = 0 or 1 in both
knees) who developed radiographic OA in either
knee at follow-up (K&L = r 2). Patients with
baseline OA (K&L = 2 or 3) and a follow-up score
which increased by r 1 grade in the same knee
were classified as having progressive OA.
Participants with baseline K&L = 4 were excluded
from the analyzes since they were not eligible to
develop incident or progressive OA. Osteophyte
growth was defined as an increase of r 1 grade
between the baseline and follow-up films.
Joint-space loss was also defined as an increase in
r 1 grade except for patients with baseline
grade = 0, for which the follow-up grade had to be
at least 2. These definitions are based on previous
analyses used to validate definitions of OA changes
over time, in which the above cut-off points were
determined to maximize the association between
definitions of radiographic OA changes and known
risk factors for radiographic knee OA [19].
igf-i measurements
Before serum IGF-I measurement by competitive
binding radio-immunoassay (RIA), IGF binding
proteins (IGFBPs) were removed using an
octadecasilyl-silica technique, as previously
described, to prevent their interference in the
assay [20]. This method has been shown to remove
more than 99% of IGFBPs [20]. Briefly, 50 ml serum
was incubated for 1–2 h with 150 ml of 0.5 n HCL.
Octadecasilyl-silica cartridges (C-18 Sep-Pak,
Millipore/Waters, Milford, MA, U.S.A.) were
pretreated sequentially with 2-propanol, methanol,
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and 4% glacial acetic acid. The 200 ml acidified
serum sample was applied to the cartridge,
incubated at room temperature for 3 min, and
drawn through the cartridge under vacuum. Each
cartridge was washed with 4% acetic acid solution
and the IGF-1 eluted with methanol. The resulting
IGF-I/methanol solution was dried overnight
under vacuum centrifugation and reconstituted
30:1 with phosphate-buffered saline. Subdilutions
of the 30:1 solution were prepared to provide three
final dilution levels for RIA (30:1, 75:1, and 150:1).
IGF-I was measured by competitive binding RIA
(Nichols Institute Diagnostics, San Juan
Capistrano, CA, U.S.A.) according to the
manufacturer’s specifications. Briefly, extracted
serum samples, standards, and controls were mixed
with primary IGF-I antibody (rabbit anti-human)
and incubated for 1 h at room temperature.
125I-IGF-I antibody was then added and incubation
continued for 16–18 h at 4 ° C. A second antibody,
(goat anti-rabbit), was added and incubated for 20
min at room temperature. Samples were
centrifuged, decanted, and precipitant pellets
counted in a gamma counter. IGF-I concentrations,
corrected for dilutions, were calculated by
reference to a standard curve generated for each
RIA kit. The mean IGF-I concentration from the
three dilutions was calculated for each subject.
The inter-assay and intra-assay variance were
9.8–11.8% and 2.3–2.9% respectively.
covariates
Baseline age and body mass index (BMI) were
examined as potential confounders since these
factors are associated both with OA and IGF-I.
BMI was calculated as weight in kilograms divided
by height in meters squared.
statistical analyses
All analyses were knee-based and sex-specific.
Because age is very strongly related to both IGF-I
and OA [10, 11], we created age-specific IGF-I
tertiles, within 2 year age groups, to ensure that
the effects of this confounder were adequately
controlled for. We used multivariate logistic
regression to examine age-adjusted IGF-I tertiles
in relation to the risk of incident and progressive
radiographic knee OA separately, adjusting for
BMI and baseline K&L score. In each case the
lowest IGF-I tertile was used as the referent
category. Generalized estimating equations were
used to adjust for the correlation between fellow
knees.
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Table II
Association of IGF-1 and incident* and progressive† OA
Women Men
Age-adjusted
IGF-1 tertile N of cases Crude OR Adjusted‡ OR N of cases Crude OR Adjusted* OR
Incident OA
Low 33 1.0 1.0 10 1.0 1.0
Middle 17 1.1 (0.7–1.9) 1.3 (0.8–2.1) 7 0.9 (0.3–2.2) 1.0 (0.4–2.5)
Highest 23 1.0 (0.6–1.7) 0.9 (0.6–1.7) 14 1.5 (0.6–3.4) 1.2 (0.6–2.6)
Progressive OA
Low 19 1.0 1.0 7 1.0 1.0
Middle 12 0.9 (0.5–1.7) 1.1 (0.6–2.0) 8 1.0 (0.3–2.8) 1.4 (0.5–4.1)
Highest 19 0.9 (0.6–1.6) 0.9 (0.5–1.6) 5 0.7 (0.2–2.3) 0.9 (0.3–3.0)
Baseline K+L score of 90 and a follow up x!ray of r 1[
$Baseline K+L score of 12 and a follow!up score which increased by r 0 grade[
%Adjusted for] body mass index\ and baseline K+L grade[
Results
IGF-I levels were measured in 293 women and
148 men. The descriptive characteristics for
subjects with and without baseline OA are
presented in Table I. As expected, IGF levels were
negatively correlated with age (r = - 0.2 for women
and r = - 0.1 for men), and positively correlated
with BMI (r = 0.05 for women and r = 0.1 for men).
There was no significant difference between IGF-I
levels between those who survived versus those
who died before obtaining repeat X-rays at exam
22. The mean IGF-I level in male survivors versus
those who died before exam 22 were
201.5 2 99.8 ng/ml versus 183.3 2 100.1 ng/ml,
P = 0.6. Similarly in women, the respective IGF-I
levels were 170.5 2 67.4 ng/ml, and
158.4 2 89.7 ng/ml, P = 0.6.
For women, 73 knees were classified as having
incident OA, and 50 were classified as having
progressive OA. For men, 31 and 20 knees were
classified as having incident and progressive
disease respectively. No associations were
observed for serum IGF-I levels with either
incident or progressive radiographic knee OA in
either sex (Table II). For example, among women
without OA at baseline, those in the highest IGF-I
tertile had an odds ratio of 0.9 (0.6–1.7) of
developing incident knee OA. For women with OA
at baseline, the odds of radiographic progression
was 0.9 (0.5–1.6). In addition, we did not observe
any association with IGF-I and individual
radiographic features (i.e. osteophyte growth and
joint space loss) in subjects with or without
baseline OA (Tables III and IV).
Discussion
In summary, this longitudinal study did not
demonstrate an association of serum IGF-I levels
and incident or progressive radiographic knee
osteoarthritis. Our findings are consistent with the
cross-sectional studies of McAlindon et al. [10] and
Hochberg et al. [11]. Other cross-sectional studies
have found both lower [9], and higher [8] mean
serum IGF-I levels in subjects with OA compared
to controls. Denko et al. [9] found that patients
with both symptomatic and radiographic OA had
lower serum levels than age, sex, race, height, and
Table III
Association of IGF-1 and osteophyte growth and joint space loss in subjects without baseline OA (K&L = 0–1)
Women Men
Age-adjusted
IGF-1 tertile N of cases Crude OR Adjusted* OR N of cases Crude OR Adjusted* OR
Osteophyte growth
Low 141 1.0 1.0 41 1.0 1.0
Middle 83 1.0 (0.6–1.9) 1.1 (0.8–1.6) 30 1.0 (0.4–2.3) 1.3 (0.6–2.8)
High 110 1.2 (0.7–2.1) 1.2 (0.8–1.7) 50 1.1 (0.5–2.4) 1.1 (0.5–2.3)
Joint space loss
Low 13 1.0 1.0 16 1.0 1.0
Middle 2 1.2 (0.2–6.3) 1.5 (0.2–9.9) 7 1.3 (0.4–4.6) 1.6 (0.5–5.0)
High 12 1.7 (0.3–8.6) 1.6 (0.3–9.1) 10 0.7 (0.2–3.4) 0.6 (0.1–2.6)
Adjusted for] body mass index\ and baseline K+L grade[
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Table IV
Association of IGF-1 and osteophyte growth + joint space loss in subjects with baseline OA (K&L r 2)
Women Men
Age-adjusted
IGF-1 tertile N of cases Crude OR Adjusted* OR N of cases Crude OR Adjusted* OR
Osteophyte growth
Low 90 1.0 1.0 32 1.0 1.0
Middle 78 1.4 (0.6–2.9) 1.5 (0.7–3.2) 38 0.9 (0.3–2.6) 1.1 (0.4–3.1)
Highest 99 1.6 (0.8–3.2) 1.6 (0.8–3.2) 32 0.9 (0.3–2.6) 1.0 (0.3–2.9)
Joint space loss
Low 31 1.0 1.0 16 1.0 1.0
Middle 17 1.3 (0.4–3.7) 1.8 (0.6–6.0) 17 0.8 (0.2–3.0) 0.8 (0.2–3.2)
Highest 33 1.4 (0.5–3.9) 1.5 (0.5–4.3) 13 1.0 (0.2–4.8) 1.1 (0.2–4.8)
Adjusted for] body mass index\ and baseline K+L grade[
weight matched controls. In contrast, Lloyd et al.
[8] found a positive association between increased
IGF-I levels and distal interphalangeal and
bilateral knee OA, but not unilateral knee, spine or
hip OA. We could not confirm the findings of
Schouten et al. [12] who found that increased
serum IGF-I levels were associated with osteophyte
growth in subjects with baseline OA (examined 12
years after baseline). Several differences between
this study and ours, including the mean age of the
participants (older in our study), radiographic
scoring techniques, IGF-I assays, and methods of
analyses, might account for the contrasting
results.
The relatively small size of our study sample
(especially for men), might have prevented us from
detecting statistically significant associations
between incident and progressive OA with IGF-I.
However, the adjusted odds ratios all
approximated 1, suggesting that we were unlikely
to miss an important association.
We measured IGF-I levels, using an assay which
is capable of removing approximately 99% of IGF-I
binding proteins, midway between baseline and
follow-up radiographs. Although it is possible that
some participants may have developed disease by
the time IGF-I was assessed, it is doubtful that
they would have been classified into different
age-adjusted IGF-I tertiles had this exposure been
measured at baseline, since serum IGF-I is unlikely
to be influenced by local disease [8].
Our results do not discount a possible important
local role of IGF-I in the pathophysiology of OA.
IGF-I has been shown to have important anabolic
effects on cartilage in in vitro experiments. It
increases chondrocyte collagen and proteoglycan
synthesis, and inhibits proteoglycan degradation
even in the presence of such potent catabolic
cytokines as interleukin-1 beta and tumor necrosis
factor alpha [1]. The lack of association between
serum levels of IGF-I and OA might be explained
by the interposition of other regulatory
mechanisms between serum IGF-I levels and
cellular access to this growth factor [21].
In conclusion, we did not find an association
between serum IGF-I levels and either incident or
progressive radiographic knee OA. Further studies
are needed to clarify the role of IGF-I in OA.
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